| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Cancer statistics, 2012.
|
CA Cancer J Clin
|
2012
|
87.38
|
|
2
|
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
|
N Engl J Med
|
2009
|
46.35
|
|
3
|
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
|
Sci Transl Med
|
2011
|
16.94
|
|
4
|
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
|
N Engl J Med
|
2013
|
14.78
|
|
5
|
Detection of mutations in EGFR in circulating lung-cancer cells.
|
N Engl J Med
|
2008
|
13.54
|
|
6
|
Analysis of circulating tumor DNA to monitor metastatic breast cancer.
|
N Engl J Med
|
2013
|
13.22
|
|
7
|
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
|
Nature
|
2012
|
10.17
|
|
8
|
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
|
J Clin Oncol
|
2011
|
8.40
|
|
9
|
Detection of circulating tumor DNA in early- and late-stage human malignancies.
|
Sci Transl Med
|
2014
|
8.36
|
|
10
|
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
|
Nature
|
2013
|
7.42
|
|
11
|
Lung cancer in never smokers: a review.
|
J Clin Oncol
|
2007
|
5.49
|
|
12
|
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
|
Nat Med
|
2014
|
4.98
|
|
13
|
Liquid biopsies: genotyping circulating tumor DNA.
|
J Clin Oncol
|
2014
|
4.76
|
|
14
|
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.
|
Cancer Res
|
2006
|
4.72
|
|
15
|
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
|
J Thorac Oncol
|
2014
|
4.54
|
|
16
|
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.
|
Clin Cancer Res
|
2011
|
4.16
|
|
17
|
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
|
J Natl Cancer Inst
|
2013
|
3.63
|
|
18
|
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
|
J Clin Oncol
|
2013
|
2.90
|
|
19
|
ALK in lung cancer: past, present, and future.
|
J Clin Oncol
|
2013
|
2.70
|
|
20
|
Survival in early-stage non-small cell lung cancer.
|
Ann Thorac Surg
|
1995
|
2.01
|
|
21
|
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
|
Clin Cancer Res
|
2015
|
1.59
|
|
22
|
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.
|
Cancer Metastasis Rev
|
2012
|
1.32
|
|
23
|
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.
|
PLoS One
|
2012
|
1.27
|
|
24
|
Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.
|
Clin Chem
|
2015
|
1.20
|
|
25
|
EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.
|
Int J Med Sci
|
2013
|
1.14
|
|
26
|
Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
|
Int J Cancer
|
2012
|
1.08
|
|
27
|
EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
|
J Thorac Oncol
|
2012
|
1.07
|
|
28
|
Treatment of lung cancer.
|
Radiol Clin North Am
|
2012
|
0.98
|
|
29
|
Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns.
|
J Thorac Oncol
|
2011
|
0.93
|
|
30
|
Circulating Tumor DNA Outperforms Circulating Tumor Cells for KRAS Mutation Detection in Thoracic Malignancies.
|
Clin Chem
|
2015
|
0.91
|
|
31
|
Plasma EGFR Mutation Detection Associated With Survival Outcomes in Advanced-Stage Lung Cancer.
|
Clin Lung Cancer
|
2015
|
0.78
|
|
32
|
Overcoming acquired resistance to kinase inhibition: the cases of EGFR, ALK and BRAF.
|
Bioorg Med Chem Lett
|
2012
|
0.77
|
|
33
|
ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.
|
Lung
|
2012
|
0.77
|